Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1979 Feb;39(2):159–167. doi: 10.1038/bjc.1979.26

Changes in nerve conduction velocity in the mouse after acute and chronic administration of nitroimidazoles.

D G Hirst, B Vojnovic, B Hobson
PMCID: PMC2009849  PMID: 435365

Abstract

The effect of the nitroimidazoles misonidazole, Ro-05-9963, RGW-608 and metronidazole on nerve conduction velocity (NCV) were measured in the anaesthetized mouse. The compounds were administered by i.p. injection either as a single dose of 1 mg/g (only 0.5 mg/g for RGW-608) or in 36 fractions of 0.15 mg/g over 18 days (only 4 fractions in 2 days for RGW-608). After single doses a reduction in nerve conduction velocity was seen with all the compounds except metronidazole, which had no significant effect. During chronic exposure, a reduction in NCV occurred towards the end of the course of injections. All compounds produced an effect, although RGW-608 was the most neurotoxic, giving the largest reduction in NCV after only 4 injections. After the end of chronic exposure to misonidazole, Ro-05-9963 and metronidazole, recovery to normal took 2-3 weeks.

Full text

PDF
159

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Asquith J. C., Dewey D. L., Foster J. L., Michael B. D., Willson R. L. Electron affinic sensitization. II. Para-nitroacetophenone: a radiosensitizer for anoxic bacterial and mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med. 1971;19(6):575–585. doi: 10.1080/09553007114550751. [DOI] [PubMed] [Google Scholar]
  2. Adams G. E., Clarke E. D., Jacobs R. S., Stratford I. J., Wallace R. G., Wardman P., Watts M. E. Mammalian cell toxicity of nitro compounds : dependence upon reduction potential. Biochem Biophys Res Commun. 1976 Oct 4;72(3):824–829. doi: 10.1016/s0006-291x(76)80207-0. [DOI] [PubMed] [Google Scholar]
  3. Adams G. E., Flockhart I. R., Smithen C. E., Stratford I. J., Wardman P., Watts M. E. Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res. 1976 Jul;67(1):9–20. [PubMed] [Google Scholar]
  4. Asquith J. C., Watts M. E., Patel K., Smithen C. E., Adams G. E. Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res. 1974 Oct;60(1):108–118. [PubMed] [Google Scholar]
  5. Chapman J. D., Reuvers A. P., Borsa J., Petkau A., McCalla D. R. Nitrofurans as radiosensitizers of hypoxic mammalian cells. Cancer Res. 1972 Dec;32(12):2616–2624. [PubMed] [Google Scholar]
  6. Coxon A., Pallis C. A. Metronidazole neuropathy. J Neurol Neurosurg Psychiatry. 1976 Apr;39(4):403–405. doi: 10.1136/jnnp.39.4.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Denekamp J., Michael B. D., Harris S. R. Hypoxic cell radiosensitizers: comparative tests of some electron affinic compounds using epidermal cell survival in vivo. Radiat Res. 1974 Oct;60(1):119–132. [PubMed] [Google Scholar]
  8. Dische S., Saunders M. I., Lee M. E., Adams G. E., Flockhart I. R. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977 May;35(5):567–579. doi: 10.1038/bjc.1977.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Flockhart I. R., Large P., Troup D., Malcolm S. L., Marten T. R. Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole. Xenobiotica. 1978 Feb;8(2):97–105. doi: 10.3109/00498257809060388. [DOI] [PubMed] [Google Scholar]
  10. Hirst D. G., Vojnovic B., Stratford I. J., Travis E. L. The effect of the radiosensitizer misonidazole on motor nerve conduction velocity in the mouse. Br J Cancer Suppl. 1978 Jun;3:237–241. [PMC free article] [PubMed] [Google Scholar]
  11. Karim A. B. Prolonged metronidazole administration with protracted radiotherapy: a pilot study on response of advanced tumours. Br J Cancer Suppl. 1978 Jun;3:299–301. [PMC free article] [PubMed] [Google Scholar]
  12. Kogelnik H. D., Meyer J. H., Jentzsch K., Szepesi T., Kärcher K. H., Maida E., Mamoli B., Wessely P., Zaunbauer F. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole. Br J Cancer Suppl. 1978 Jun;3:281–285. [PMC free article] [PubMed] [Google Scholar]
  13. McNally N. J., Denekamp J., Sheldon P. W., Flockhart I. R. Hypoxic cell sensitization by misonidazole in vivo and in vitro. Br J Radiol. 1978 Apr;51(604):317–318. doi: 10.1259/0007-1285-51-604-317. [DOI] [PubMed] [Google Scholar]
  14. Rauth A. M., Kaufman K. In vivo testing of hypoxic radiosensitizers using the KHT murine tumour assayed by the lung-colony technique. Br J Radiol. 1975 Mar;48(567):209–220. doi: 10.1259/0007-1285-48-567-209. [DOI] [PubMed] [Google Scholar]
  15. Snyder D. R., Gralla E. J., Coleman G. L. Preliminary neurological evaluation of generalized weakness in zinc pyrithione-treated rats. Food Cosmet Toxicol. 1977 Feb;15(1):43–47. doi: 10.1016/s0015-6264(77)80262-9. [DOI] [PubMed] [Google Scholar]
  16. Urtasun R. C., Band P., Chapman J. D., Rabin H. R., Wilson A. F., Fryer C. G. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology. 1977 Mar;122(3):801–804. doi: 10.1148/122.3.801. [DOI] [PubMed] [Google Scholar]
  17. Urtasun R. C., Chapman J. D., Band P., Rabin H. R., Fryer C. G., Sturmwind J. Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells. Radiology. 1975 Oct;117(1):129–133. doi: 10.1148/117.1.129. [DOI] [PubMed] [Google Scholar]
  18. Urtasun R. C., Chapman J. D., Feldstein M. L., Band R. P., Rabin H. R., Wilson A. F., Marynowski B., Starreveld E., Shnitka T. Peripheral neuropathy related to misonidazole: incidence and pathology. Br J Cancer Suppl. 1978 Jun;3:271–275. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES